Patterson RE, et al. - Researchers investigated how metformin vs placebo and a weight loss intervention vs control (ie, usual care) influence biomarkers associated with breast cancer prognosis in overweight/obese postmenopausal breast cancer survivors (n=333). They used 2 × 2 factorial design and performed a single randomized trial with changes in fasting insulin, glucose, C-reactive protein (CRP), estradiol, testosterone, and sex-hormone binding globulin (SHBG) as the outcomes. They found that implementation of this combination strategy (ie, weight loss and metformin) as adjuvant therapy enabled safe and modest lowering of estrogen levels. Moreover, this strategy advantageously influenced other biomarkers thought to be on the pathway for reducing breast cancer recurrence and mortality.